Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.66 |
| ▸ | RAF1 | P04049 | 2/20 | 0.63 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27243368 | 1.00 | KRAS (0.66) | KRASRAF1MAPK3MAPK1 | |
| SCHEMBL27387526 | 1.00 | KRAS (0.66) | KRASRAF1MAPK3MAPK1 | |
| SCHEMBL27243413 | 1.00 | KRAS (0.66) | KRASRAF1MAPK3MAPK1 | |
| SCHEMBL30810127 | 0.93 | KRAS (0.65) | KRASRAF1MAPK3MAPK1 | |
| SCHEMBL27243292 | 0.93 | KRAS (0.75) | KRASRAF1MAPK3MAPK1 | |
| SCHEMBL27243167 | 0.93 | KRAS (0.65) | KRASRAF1MAPK3MAPK1 | |
| SCHEMBL30810060 | 0.93 | KRAS (0.75) | KRASRAF1MAPK3MAPK1 | |
| SCHEMBL24712650 | 0.93 | KRAS (0.61) | KRASRAF1MAPK3MAPK1 | |
| SCHEMBL27243326 | 0.92 | KRAS (0.64) | KRASRAF1MAPK3MAPK1 | |
| SCHEMBL27243162 | 0.92 | KRAS (0.64) | KRASRAF1MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4573089-A2 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-06-25 | — | — | EP | claimed |
| CN-119998275-A | KRAS inhibitors | 百时美施贵宝公司 | 2025-05-13 | — | — | CN | claimed |
| WO-2024040109-A2 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-22 | — | — | WO | claimed |
| EP-4573089-A2 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-119998275-A | KRAS inhibitors | 百时美施贵宝公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240199584-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-06-20 | — | — | US | disclosed |
| WO-2024040109-A2 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199584-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885RAF1 16/4885MAPK3 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.